La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CSL Gestione

Gestione criteri di controllo 1/4

CSL's Il CEO è Paul McKenzie, nominato in Mar2023, e ha un mandato di 1.42 anni. la retribuzione annua totale è $ 8.18M, composta da 23.1% di stipendio e 76.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.005% delle azioni della società, per un valore di A$ 6.92M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 4.7 anni.

Informazioni chiave

Paul McKenzie

Amministratore delegato

US$8.2m

Compenso totale

Percentuale dello stipendio del CEO	23.1%
Mandato del CEO	1.5yrs
Proprietà del CEO	0.006%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul McKenzie rispetto agli utili di CSL?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 8.18M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 4.17M ).

Compensazione vs guadagni: La retribuzione di Paul è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Paul McKenzie (58 yo)

1.5yrs

Mandato

US$8,183,842

Compensazione

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul McKenzie	MD, CEO & Executive Director	1.5yrs	US$8.18m	0.0056% $ 7.7m
Joy Linton	Interim Executive Vice President of CSL Behring	no data	US$3.73m	0.0025% $ 3.4m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.2yrs	US$4.07m	0.00044% $ 607.4k
John A. Levy	Interim Chief Financial Officer	no data	Nessun dato	Nessun dato
Chris Cooper	Head of Investor Relations	no data	Nessun dato	Nessun dato
Gregory Boss	Executive VP of Legal & General Counsel	15.7yrs	US$2.31m	Nessun dato
Roanne Parry	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Karen Etchberger	Executive Vice President of Quality & Business Services	14.4yrs	US$2.14m	Nessun dato
Jemimah Brennan	Head of Communications - Asia Pacific	no data	Nessun dato	Nessun dato
Andrew Nash	Senior Vice President of Research	no data	Nessun dato	Nessun dato
William Mezzanotte	Executive VP & Head of Research and Development	5.9yrs	US$2.14m	Nessun dato
Mark Hill	Chief Digital Information Officer & Executive VP	3.9yrs	Nessun dato	Nessun dato

1.5yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di CSL non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul McKenzie	MD, CEO & Executive Director	1.8yrs	US$8.18m	0.0056% $ 7.7m
Megan Clark	Independent Non Executive Director	8.6yrs	US$242.44k	0.0011% $ 1.5m
Alison Watkins	Independent Non-Executive Director	3.1yrs	US$240.56k	0.00077% $ 1.1m
Carolyn Hewson	Independent Non-Executive Director	4.8yrs	US$237.09k	0.00047% $ 648.8k
Brian McNamee	Independent Non-Executive Chairman	6.6yrs	US$604.85k	0.026% $ 36.1m
Robert Cuthbertson	Non-Independent Non-Executive Director	5.9yrs	US$221.35k	0.015% $ 20.2m
Duncan Maskell	Independent Non-Executive Director	3.1yrs	US$190.94k	0.00035% $ 483.2k
Marie McDonald	Independent Non-Executive Director	11.1yrs	US$215.19k	0.00088% $ 1.2m
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% $ 566.0k
Elaine Sorg	Independent Non-Executive Director	no data	Nessun dato	Nessun dato

3.9yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CSL sono considerati esperti (durata media dell'incarico 4.7 anni).

CSL Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

Recent updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.